Hereditary angioedema (HAE) is a rare and potentially life-threatening disorder caused by deficiency or dysfunction of complement 1 esterase inhibitor (C1-INH) in plasma. This activity is designed to update primary care nurse practitioners (NPs) and physician assistants (PAs) on early diagnosis and new options to improve treatment and prophylaxis.
eNewsletter with interactive benchmarking
To present diagnostic approaches to improve early diagnosis of HAE and describe recent developments in pharmacotherapy for this rare and disabling disorder
After completing this activity, participants should be better able to:
- Describe the pathophysiology and clinical threat of HAE, including factors that distinguish it from more common causes of angioedema
- Identify risk factors and triggers for HAE in order to establish a more accurate and early diagnosis
- Formulate strategies for the prevention and treatment of HAE, taking individual patient factors and preferences into account
NPs and PAs
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
CNE course advisor: Susanne J. Phillips, DNP, APRN, FNP-BC, University of California, Irvine
This program has been reviewed and is approved for a maximum of 1.00 of AAPA Category 1 CME credits by the AAPA Review Panel. Approval is valid for one year from the issue date of September 14, 2017. Participants may submit the post-test at any time during that period.
This program was planned in accordance with AAPA CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.
This activity is supported by an independent educational grant from Shire.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance, Practicing Clinicians Exchange, the AAPA, or Shire.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Riedl: consulting fees: Adverum, Alnylam, Arrowhead, BioCryst, CSL Behring, Ionis, KalVista, Pharming, Shire; honoraria: CSL Behring, Pharming, Shire; research funding: BioCryst, CSL Behring, Pharming, Shire.
The planning committee for this activity included Ruth Cohen and Margaret Inman of Continuing Education Alliance; Susanne J. Phillips, DNP, APRN, FNP-BC, of the University of California, Irvine; and Mark Christiansen, PhD, PA-C, of the University of the Pacific. The members of the planning committee have no significant relationships to disclose.
Participants wishing to earn CE/CME credit must:
- Read the eNewsletter in its entirety
- Relate the content material to the learning objectives
- Complete the post-test and evaluation form online
Successful completion of the post-test is required to earn CE/CME credit. Successful completion is defined as a cumulative score of at least 70%.
The estimated time to complete this activity is 1.00 hours.
Release date: September 14, 2017
Expiration date: September 14, 2018
© 2018 Practicing Clinicians Exchange. All Rights Reserved. SHPCE92617